Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05155254
Title IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors IO Biotech
Indications

melanoma

Therapies

IO102-IO103 + Pembrolizumab

Pembrolizumab

Age Groups: senior | adult
Covered Countries USA | FRA | ESP


No variant requirements are available.